RU97108687A - COMPOSITIONS OF CISAPRID WITH LONG-TERM RELEASE OF THE ACTIVE SUBSTANCE FOR ORAL ADMINISTRATION - Google Patents

COMPOSITIONS OF CISAPRID WITH LONG-TERM RELEASE OF THE ACTIVE SUBSTANCE FOR ORAL ADMINISTRATION

Info

Publication number
RU97108687A
RU97108687A RU97108687/14A RU97108687A RU97108687A RU 97108687 A RU97108687 A RU 97108687A RU 97108687/14 A RU97108687/14 A RU 97108687/14A RU 97108687 A RU97108687 A RU 97108687A RU 97108687 A RU97108687 A RU 97108687A
Authority
RU
Russia
Prior art keywords
active substance
composition
cellulose
substance according
approximately
Prior art date
Application number
RU97108687/14A
Other languages
Russian (ru)
Other versions
RU2143890C1 (en
Inventor
Мари Йозеф Янс Эжен
Мари Виктор Гилис Поль
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Priority claimed from PCT/EP1995/004198 external-priority patent/WO1996014070A1/en
Publication of RU97108687A publication Critical patent/RU97108687A/en
Application granted granted Critical
Publication of RU2143890C1 publication Critical patent/RU2143890C1/en

Links

Claims (10)

1. Композиция с длительным высвобождением действующего вещества, включающая цисаприд-(L)-тартрат, подходящая для перорального введения.1. Composition with prolonged release of the active substance, including cisapride- (L) -tartrate, suitable for oral administration. 2. Композиция с длительным высвобождением действующего вещества по п. 1, включающая смесь гидроксипропилметилцеллюлозы и другого вязкого полимера целлюлозы. 2. A composition for the sustained release of the active substance according to claim 1, comprising a mixture of hydroxypropyl methylcellulose and another viscous cellulose polymer. 3. Композиция с длительным высвобождением действующего вещества по п. 2, включающая смесь гидроксипропилметилцеллюлозы и гидроксипропилцеллюлозы. 3. A composition for the sustained release of the active substance according to claim 2, comprising a mixture of hydroxypropyl methylcellulose and hydroxypropyl cellulose. 4. Композиция с длительным высвобождением действующего вещества по п. 2, в которой ядро композиции включает от 15 до 35% смеси гидроксипропилметилцеллюлозы и другого вязкого полимера целлюлозы. 4. A composition for the sustained release of the active substance according to claim 2, wherein the core of the composition comprises from 15 to 35% of a mixture of hydroxypropyl methylcellulose and another viscous cellulose polymer. 5. Композиция с длительным высвобождением действующего вещества по п. 4, в которой отношение массы гидроксипропилметилцеллюлозы к массе гидроксипропилцеллюлозы составляет в интервале от приблизительно 0,33 до приблизительно 3. 5. The composition for prolonged release of the active substance according to claim 4, in which the ratio of the mass of hydroxypropylmethyl cellulose to the mass of hydroxypropyl cellulose is in the range from about 0.33 to about 3. 6. Композиция с длительным высвобождением действующего вещества по п. 5, в которой отношение массы гидроксипропилметилцеллюлозы к массе гидроксипропилцеллюлозы составляет приблизительно 1. 6. A composition for the sustained release of the active substance according to claim 5, in which the ratio of the mass of hydroxypropylmethyl cellulose to the mass of hydroxypropyl cellulose is approximately 1. 7. Композиция с длительным высвобождением действующего вещества по любому из пп. 1 - 4, включающая:
Цисаприд-(L)-тартрат; - Приблизительно 9 мас.%
Лактоза - Приблизительно 61 мас.%
Гидроксипропилметилцеллюлоза - 5,5 - 18 мас.%
Гидроксипропилцеллюлоза - 5,5 - 18 мас.%
Смазки - Приблизительно 6,5 мас.%
причем общий процент (мас.) производных целлюлозы составляет приблизительно 23,5%.7. Composition with prolonged release of the active substance according to any one of paragraphs. 1 to 4, including:
Cisapride- (L) tartrate; - About 9 wt.%
Lactose - Approximately 61 wt.%
Hydroxypropyl methylcellulose - 5.5 - 18 wt.%
Hydroxypropyl cellulose - 5.5 - 18 wt.%
Lubricants - Approximately 6.5 wt.%
moreover, the total percentage (wt.) derivatives of cellulose is approximately 23.5%. 8. Кристаллическая форма цисаприд-(L)-тартрата, в которой диастереомеры вида [(3R4S) (2RЗR)] и [(3S4R) (2RЗR)] кристаллизуются в виде двойной соли в соотношении 1:1. 8. The crystalline form of cisapride- (L) -tartrate, in which diastereomers of the form [(3R4S) (2RЗR)] and [(3S4R) (2RЗR)] crystallize as a double salt in a 1: 1 ratio. 9. Способ получения композиции с длительным высвобождением действующего вещества, заявленной в любом из пп. 1 - 7, отличающийся тем, что активный ингредиент тщательно смешивают с другими фармацевтически приемлемыми ингредиентами. 9. A method of obtaining a composition with prolonged release of the active substance, as claimed in any one of paragraphs. 1 to 7, characterized in that the active ingredient is thoroughly mixed with other pharmaceutically acceptable ingredients. 10. Применение композиции по любому из пп. 1 - 7 в качестве лекарственного средства, особенно для лечения желудочно-кишечных заболеваний. 10. The use of the composition according to any one of paragraphs. 1 - 7 as a medicine, especially for the treatment of gastrointestinal diseases.
RU97108687/14A 1994-11-02 1995-10-25 Cisaprid composition of prolonged release of active substance for oral administration and method of its preparing RU2143890C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203184.0 1994-11-02
EP94203184 1994-11-02
PCT/EP1995/004198 WO1996014070A1 (en) 1994-11-02 1995-10-25 Cisapride extended release oral compositions

Publications (2)

Publication Number Publication Date
RU97108687A true RU97108687A (en) 1999-05-27
RU2143890C1 RU2143890C1 (en) 2000-01-10

Family

ID=8217338

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97108687/14A RU2143890C1 (en) 1994-11-02 1995-10-25 Cisaprid composition of prolonged release of active substance for oral administration and method of its preparing

Country Status (29)

Country Link
US (2) US6153623A (en)
EP (1) EP0789572A1 (en)
JP (1) JP3182423B2 (en)
KR (1) KR100255521B1 (en)
AP (1) AP658A (en)
AR (1) AR001765A1 (en)
AU (1) AU704284B2 (en)
BG (1) BG63244B1 (en)
BR (1) BR9509565A (en)
CA (1) CA2203663C (en)
CZ (1) CZ287844B6 (en)
EE (1) EE03510B1 (en)
FI (1) FI971856A0 (en)
HR (1) HRP950539A2 (en)
HU (1) HUT77887A (en)
IL (1) IL115843A0 (en)
MY (1) MY113092A (en)
NO (1) NO312538B1 (en)
NZ (1) NZ295166A (en)
OA (1) OA10419A (en)
PL (1) PL181470B1 (en)
RO (1) RO116042B1 (en)
RU (1) RU2143890C1 (en)
SK (1) SK54297A3 (en)
TR (1) TR199501351A2 (en)
TW (1) TW466114B (en)
UA (1) UA50721C2 (en)
WO (1) WO1996014070A1 (en)
ZA (1) ZA959221B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
US6126970A (en) * 1995-12-01 2000-10-03 Janssen Pharmaceutica N.V. Cisapride sustained release
DE69713948D1 (en) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rapidly releasing pH-independent solid dosage forms containing cisapride
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
EP0988032A1 (en) * 1997-06-11 2000-03-29 Janssen Pharmaceutica N.V. IMMEDIATE RELEASE pH-INDEPENDENT SOLID DOSAGE FORM OF (+)- OR (-)-CISAPRIDE
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
EP1060743A1 (en) * 1999-06-17 2000-12-20 Development Center For Biotechnology Oral cisapride dosage forms with an extended duration
NZ524641A (en) 2000-09-29 2004-09-24 Solvay Pharmaceuticals B A pharmaceutical hydrophilic gel forming matrix formulation having prolonged release which is ion strength independent
ATE408400T1 (en) * 2002-05-21 2008-10-15 Watson Lab Inc DELAYED RELEASE PHARMACEUTICAL COMPOSITION
US8617596B2 (en) 2006-04-12 2013-12-31 Nippon Soda Co., Ltd. Sustained-release tablet production process
RU2356532C2 (en) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Controlled-release pharmaceutical proxodolol composition
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ATE173159T1 (en) * 1992-03-25 1998-11-15 Depomed Systems Inc ORAL MEDICINAL DOSAGE FORMS BASED ON HYDROXYETHYL CELLULOSE WITH DELAYED RELEASE
JPH08502032A (en) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド Method of using ▲ (−) ▼ cisapride for treating gastroesophageal reflux disease and other disorders
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Similar Documents

Publication Publication Date Title
JPH0567612B2 (en)
JP2619936B2 (en) Novel pharmaceutical preparation and its manufacturing method
JP2764451B2 (en) Synergistic composition for treatment of periodontal disease and method of treatment
KR890004688B1 (en) Sustained release pharmaceutical carrier compositions
US20070196472A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
RU97108687A (en) COMPOSITIONS OF CISAPRID WITH LONG-TERM RELEASE OF THE ACTIVE SUBSTANCE FOR ORAL ADMINISTRATION
HU206265B (en) Process for producing pharmaceutical compositions comprising morphine
IL149496A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
EA007299B1 (en) Solid orodispersible pharmaceutical composition comprising agomelatine
CA2450359A1 (en) Dosage regimen and pharmaceutical composition for emergency contraception
US3865935A (en) Tableting of erythromycin base
RU2143890C1 (en) Cisaprid composition of prolonged release of active substance for oral administration and method of its preparing
KR100263284B1 (en) More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
EP0194202A1 (en) Pharmaceutical composition of guar gum and other antacids for the protection of the oeso-gastro-duodenal mucous membrane
RU2001111808A (en) PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF ROTARY AND LEFT ROTARY ISOMERS OF SOTALOL
JPH0635383B2 (en) Controlled release tablets of ketoprofen for oral administration and method of making the same
DE3517820A1 (en) PHARMACEUTICAL PREPARATIONS WITH ANTI-HYPERTENSIVE AND CARDIOPROTECTIVE EFFECT
JPH07267839A (en) Ointment composition adhesive to oral mucosa
CA1334933C (en) Pharmaceutical composition and process for its preparation
DE4319438C1 (en) Analgesic and/or antiinflammatory medicaments - contg. sepd enantiomers of ketoprofen
JP2665357B2 (en) Pharmaceutical composition for treating heart failure
JPH0148245B2 (en)
JPH10338638A (en) Preparation for damaged skin restoration
US20050020569A1 (en) Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
WO2005023236A1 (en) Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions